Paper Details

  1. Home
  2. Paper Details

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.

Author: BusschotsSteven, DohertyBen, HallNeville, KalachandRoshni, KaprosEvangelos, LawlorDenise, PatelAashna, StordalBritta K

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ovarian cancer is a major health concern, affecting many women worldwide. The most common type is epithelial ovarian cancer. While the standard treatment is surgery followed by chemotherapy, over half of women experience a relapse, needing more chemotherapy. We need clearer guidance on using chemotherapy drugs, including taxanes, for women with recurrent ovarian cancer. Taxanes can be given in different ways, which might have different side effects and effectiveness. Since these cancers are often incurable, it's important to consider the side effects, quality of life, and overall impact of treatment, not just how long it prolongs life.
Paper Details　
Original Abstract of the Article :
Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreduc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309650/

データ提供：米国国立医学図書館（NLM）

Navigating the Treatment of Recurrent Ovarian Cancer: Taxane Monotherapy Regimens

Ovarian cancer, like a hidden oasis in a vast desert, can be challenging to diagnose and treat. This review explores the use of taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer, a condition that often presents a significant challenge to clinicians. The authors discuss the current evidence for using taxanes in relapsed ovarian cancer, emphasizing the need for individualized treatment plans that consider both the potential benefits and side effects of treatment.

Taxane Monotherapy: A Potential Option for Relapsed Ovarian Cancer

The review highlights the potential role of taxane monotherapy as a treatment option for recurrent epithelial ovarian cancer. While platinum-based drugs are often the first-line treatment for ovarian cancer, many patients develop resistance to these medications. Taxanes, such as paclitaxel, can be an effective alternative treatment, offering hope for patients who have progressed beyond initial therapies.

Balancing Benefits and Risks in Ovarian Cancer Treatment

The review emphasizes the importance of balancing the potential benefits and risks of taxane monotherapy in the treatment of recurrent ovarian cancer. While taxanes can be effective in slowing disease progression and improving survival, they can also cause significant side effects. Open communication between patients and their healthcare providers is crucial in making informed decisions about treatment options, ensuring that patients receive the care that is most appropriate for their individual needs and preferences.

Dr.Camel's Conclusion

The treatment of recurrent ovarian cancer is a complex and often challenging journey. This review provides a valuable overview of the current evidence for using taxane monotherapy regimens, highlighting both the potential benefits and risks of this approach. By carefully considering individual patient characteristics, treatment goals, and potential side effects, we can work collaboratively with patients to develop personalized treatment plans that offer the best chance for success.

Date :
  1. Date Completed 2022-07-25
  2. Date Revised 2023-07-13
Further Info :

Pubmed ID

35866378

DOI: Digital Object Identifier

PMC9309650

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.